Therapeutic inhibition of angiopoietin-like protein 3 for hypertriglyceridaemia and residual risk of ASCVD: beginning of the end or end of the beginning?
- PMID: 38446991
- DOI: 10.1093/eurjpc/zwae095
Therapeutic inhibition of angiopoietin-like protein 3 for hypertriglyceridaemia and residual risk of ASCVD: beginning of the end or end of the beginning?
Conflict of interest statement
Conflict of interest: G.F.W. has received honoraria for lectures, advisory boards or research grants from Amgen Inc., Arrowhead, AstraZeneca, Esperion, Kowa, Novartis, Regeneron, and Sanofi. D.C.C. does not declare any conflict of interest.
Comment on
-
Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial.Eur J Prev Cardiol. 2024 Aug 9;31(10):1216-1223. doi: 10.1093/eurjpc/zwae090. Eur J Prev Cardiol. 2024. PMID: 38484368 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
